PARIS, France – June 1st, 2017 – POPSICUBE sarl, offering efficient and innovative clinical, and consulting services to the healthcare industry, today announced it has completed the acquisition of FOVEA SAS, a recognized French leader of drug development services to the pharmaceutical, biotechnology, and medical device industries. Financial terms of the transaction were not disclosed.
The acquisition makes POPSICUBE-FOVEA one of the top contract research organizations (CRO) in France with offices in USA and CHINA with an objectives to stronger its position in Europe.
Overall, POPSICUBE-FOVEA will have annual revenues of nearly $5 million across its four business segments: Clinical Services, Outsourcing, Home care trial and clinical eTools software developments.
“POPSICUBE-FOVEA growth is fueled by pharmaceutical and biotech clients who are looking to gain flexibility and efficiency through innovative, complementary and efficient services,” said Fabrice Beauchêne, Chief Executive Officer of POPSICUBE-FOVEA. “POPSICUBE-FOVEA is well positioned to serve the diverse needs of the marketplace—from smaller biotechs or medtech to the largest global enterprises, at any stage of clinical development, with capabilities to act everywhere with some key long term CRO partners.”
POPSICUBE-FOVEA’s Clinical segment offers a full suite of services that support bioanalysis, Phase II through Phase IV (post-launch) clinical trials. It offers those services across an array of therapeutic areas, including oncology, neuroscience/pain, rheumatology, infectious disease, cardiovascular, endocrinology and metabolic disease and with the expertise in new technology (Biocaptors, popsipen, validated secured datagateway… Depending on client need, POPSICUBE-FOVEA can manage a completely outsourced clinical trial, or it can provide functional support to in-house or in-home trials in such areas as clinical trial management and monitoring, data management, biostatistics solutions, regulatory and quality consulting, safety and pharmacovigilance, and patient and investigator recruitment.
Sylvie Kahn, WW Operation Directors, who will lead POPSICUBE-FOVEA Clinical and IT segment said, “We are excited to join forces with FOVEA experiences employee. As we think about our expanded capabilities, one thing won’t change: our focus on efficiency for better servicing our customers. Our combined organizations offer clients the dynamics and new technology provide by POPSICUBE with the experienced (29 year old) FOVEA providing high quality and seniority of resources and a proven track record of high quality work.”
FOVEA is POPSICUBE’s second acquisition since 2014. In Marsh 2014, POPSICUBE added MISSION TEC to its services segment. MISSION TEC is a leading European company in Home Care clinical trial with 88 clinical nurses bringing clinical study at the Home of the patients. Today POPSICUBE-FOVEA’s cross-functional, global expertise positions it as the partner-of-choice for clients developing new treatment, creating winning business strategies or bringing products to market anywhere in the world.
POPSICUBE sarl. is a challenger independent CRO, created in 2004, promoting efficiency and new technology solutions for clinical, consulting, eTools services to all size companies seeking to transform idea into a product in the market. POPSICUBE’s client roster includes more than 150 pharmaceutical, biotech, medtech and life sciences companies.
About FOVEA (acquired by POPSI CUBE)
FOVEA is a key partner of Health Industries since 1988, FOVEA is a global Clinical Research Provider offering pre-registration studies services (phase I to III clinical studies) up to post-registration studies services (interventional phase IV clinical studies and non-interventional studies, registries, epidemiological surveys, observational studies, quality of life studies, pharmaco-economic studies in several European countries. FOVEA obtained the ISO 9001 Certification of its Quality System on December 7th, 2000 (1994 edition) thus becoming one of the very first CROs certified in France and quality improvement is continuing …